Alzheimer’s Disease

ALZ-NET: examining novel approved treatments in the real-world

Topline donanemab results: most positive Phase III data to date

Overcoming the limitations of iPSC models

Impact of APOE4 on cellular function in astrocytes and microglia

Alzheimer’s disease functional genomics with iPSCs

Unveiling the role of astrocytes in Alzheimer’s disease for novel therapeutic strategies

Unravelling sex and gender differences in brain and mental diseases

Next-generation anti-amyloid therapies: prioritizing selectivity

Anti-amyloid combination strategies in Alzheimer’s disease

Sex differences in Alzheimer’s disease: women’s journey, challenges, and implications

Detecting retinal Aβ: a promising path for non-invasive Alzheimer’s disease diagnosis

Development of Appropriate Use Recommendations for lecanemab

The potential of calcineurin inhibitors in reducing the prevalence of dementia.

Prospects for Alzheimer’s disease monitoring and treatment in 2023

Why target vascular dysfunction in Alzheimer’s disease?

Unleashing the potential of microglia as a therapeutic target